Axsome Therapeutics, Inc.AXSMNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank17
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P17
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-2.03%
202491.00%
202369.02%
2022-0.20%
2021-17.34%
202030.94%
2019128.33%
201817.72%
2017-5.86%
2016212.82%